Sanofi Bulks Up Oncology Development With Avila Collaboration
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi-Aventis adds to its expertise in oncology by striking a deal with Massachusetts-based Avila Therapeutics for the biotech's covalent-bonding technology in a deal that could be worth up to $800 million.